Hyaluronic Acid Injections for Vulvar Atrophy and Intimate Pain

Hyaluronic Acid Injections Emerge as Non-Hormonal Option for Vulvovaginal Atrophy

Pain during sexual intercourse can become severe enough to lead women to abandon intimacy altogether, iodonna.it reported. According to specialists, this discomfort frequently extends beyond the bedroom, making cycling, exercising, wearing tight clothing, or simply sitting down uncomfortable.

The condition stems from the thinning, drying, and friction-sensitivity of vulvar tissues, a hallmark of vulvovaginal atrophy. While commonly associated with postmenopause, the condition also affects younger women due to hormonal shifts, gynecological disorders, or specific drug treatments.

Medical researchers and clinicians are evaluating non-hormonal interventions to address these symptoms, focusing particularly on hyaluronic acid injections into the vulvar vestibule. This procedure aims to restore tissue hydration and elasticity, potentially reducing pain during intercourse.

Estrogen Decline Causes Tissue Thinning and Dryness

As estrogen levels decline, vaginal and vulvar tissues gradually lose their natural elasticity and moisture content. The mucosa becomes thin and fragile, reducing natural lubrication and triggering dryness, burning, itching, and penetration pain.

In postmenopausal women, these physical changes fall under the genitourinary syndrome of menopause, a classification encompassing both genital and urinary symptoms. However, younger populations face similar challenges.

Today there are many pathologies that expose women, even before a certain age, to these problems, due to pharmacological treatments, hormonal imbalances, or the pathology itself, noted plastic surgeon Valentina Finotti, a specialist in regenerative medicine and injectable treatments.

Finotti also emphasized that tissue alterations linked to scars and vulvar diseases require careful clinical differentiation, as underlying causes dictate treatment paths.

Hyaluxelle Uses Thermally Processed Hyaluronic Acid

A specialized hyaluronic acid formulation called Hyaluxelle has been developed specifically for the vulvar vestibule. The medical device contains 64 mg of hyaluronic acid suspended in 2 ml, combining high and low molecular weight molecules.

The characteristic is that this hyaluronic acid is thermally processed. The union of low and high molecular weight molecules creates a hybrid, Finotti explained.

The underlying thermal technology, known as NAHYCO, constructs cooperative hybrid complexes without chemical reagents during the initial phase. Specialists report that the treatment aims to stimulate tissue elasticity rather than simply provide temporary moisture.

The standard clinical protocol involves two sessions scheduled approximately 30 days apart, followed by a six-month evaluation. Doctors apply topical anesthetic creams to the highly absorbent mucosal tissue of the vestibule before performing deep dermal injections into vulnerable areas like the posterior fourchette.

Studies Show Improved Genital Symptoms and Sexual Function

Early scientific literature offers preliminary data regarding hybrid hyaluronic acid complexes applied to the vulvar vestibule. A 2020 study published in Medical Devices: Evidence and Research tracked 26 premenopausal and postmenopausal women with vulvovaginal atrophy across two treatment sessions, noting improvements in genital symptoms and sexual function scores. The study included follow-ups for up to one year, though the number of women available for the final evaluation was limited.

A subsequent 2023 study published in Health Science Reports involved 60 participants divided between an injection group and a saline control group, observing improvements in pain, lubrication, desire, and satisfaction. The average participant age was roughly 33 in the treatment group and 29 in the control group, pointing to utility outside of menopausal cohorts.

Additional technical documentation appeared in a 2023 publication in Aesthetic Medicine. Despite these findings, researchers emphasize that existing trials involve small patient cohorts, leaving long-term durability and comparative efficacy against established therapies unconfirmed.

Hormonal Therapies Offer Established Options for Deficiency Symptoms

Low-dose vaginal estrogen remains an established, highly supported therapy for estrogen-deficiency symptoms, with more extensive clinical evidence than injectable alternatives. Fadin noted that systemic hormone replacement therapy does not always control local genital symptoms, making localized hormone administration necessary.

While hyaluronic acid injections operate through a non-hormonal mechanism, specialists view them as a potential alternative or a complementary option for selected patients. However, experts stress that medical evaluation must precede any procedure.